Total: $2,301.257M

Company (Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)@


Adherex Technologies Inc. (Canada; TSE:AHX)

Private placement of convertible notes

N/A

C$3
(US$2.2)

Adherex raised about US$2.2M in the private placement (6/24)

AMDL Inc.
(AMEX:ADL)

Private placement of units

2.6S

$0.887

AMDL raised about $887,000 net in a private offering of units consisting of convertible notes and stock purchase warrants; the notes were converted into 2.6M shares (6/23)

Amylin Pharmaceuticals
Inc.
(AMLN)

Private placement of convertible senior notes

N/A

$150

Amylin raised $150M in a private placement of 2.25% convertible senior notes due 2008 (6/18)

Axonyx Inc.
(AXYX)

Private placement of common stock and exercise of warrants

0.23S, 0.9S and W for 0.46S

$2.9

Axonyx raised $2.9M through the exercise of outstanding warrants and the placement of common shares and warrants (6/13)

BioMarin Pharmaceutical
Inc.
(BMRN)

Private placement of convertible subordinated notes

N/A

$125

BioMarin raised $125M in a private placement of convertible subordinated notes due 2008 (6/17)

Bioniche Life
Sciences Inc.
(Canada; TSE:BNC)

Private placement of common stock and warrants

1.2S and W for 0.3S

C$2.2 (US$1.6)

Bioniche raised US$1.6M with the placement of 1.2M shares; investors also received 306,250 three-year warrants to purchase common shares (6/9)

Biota Holdings Ltd. (Australia; ASX:BTA)

Private placement of common stock

5.6S

A$2.5 (US$1.6)

Biota Holdings raised US$1.6M with the placement of 5.6M shares to a subsidiary of Babcock & Brown Pty. Ltd. (6/10)

Cell Therapeutics
Inc.
(CTIC)

Private placement of convertible senior subordinated notes

N/A

$75

Cell Therapeutics raised $75M in the sale of 4% convertible senior subordinated notes due 2010 (6/18)

Cephalon Inc.
(CEPH)

Private placement of convertible subordinated notes

N/A

$750

Cephalon priced $600M worth of convertible subordinated notes, which will be issued in two tranches (6/6); the purchaser exercised an option to purchase an additional $150M in notes (6/13)

Cobra BioManufacturing plc (UK; LSE:CBF)

Private placement of common stock

6.5S

£4.65 (US$7.4)

Cobra raised US$7.4M through the sale of 6.5M shares (6/4**)

ConjuChem Inc. (Canada; TSE:CJC)

Private placement of common stock

7.5S

C$12 (US$8.9)

ConjuChem raised US$8.9M after entering an agreement to privately place 7.5M shares with a syndicate of underwriters led by Yorkton Securities Inc. (6/13)

Corixa Corp.
(CRXA)

Private placements of common stock and convertible subordinated notes

3.7S

$130

Corixa raised about $30 million through the issuance of shares to The Sprout Group, and another $85M through the placement of notes with unspecified instutional buyers (6/10); it raised another $15M through the exercise of the overallotment option (6/23)

CV Therapeutics
Inc. (CVTX)

Private placement of senior subordinated convertible debentures

N/A

$100

CV raised $100M through the sale of senior subordinated convertible debentures (6/13)

Cytogen Corp.
(CYTO)

Private placement of common stock and warrants

1S and W for 0.3S

$5

Cytogen raised $5M with the placement of 1M shares; investors also will receive warrants to purchase 315,790 shares (6/9)

Dendreon Corp. (DNDN)

Private placement of common stock

4.4S

$30.7

Dendreon raised $30.7M through the sale of 4.4M shares to Baystar Capital, Mazama Capital Management and an existing shareholder (6/13)

Discovery Laboratories Inc. (DSCO)

Private placement of common stock and warrants

5S and W for 1S

$27.5

Discovery Laboratories raised $27.5M through the private placement, which included Quaker BioVentures Inc., BayStar Capital Management LLC, Special Situations Funds, PharmaBio Development Inc., Laboratorios Del Dr. Esteve and other selected investors; Gerard Klauer Mattison & Co. acted as the placement agent (6/20)

Durect Corp.
(DRRX)

Private placement of convertible notes

N/A

$50

Durect raised $50M through the placement of convertible notes (6/13)

Generex
Biotechnology
Corp.
(GNBT)

Private placement of common stock and warrants

0.667S

$1

Generex raised $1M through the placement of 666,667 common shares to an existing accredited institutional investor (6/10)

Guilford Pharmaceuticals
Inc.
(GLFD)

Private placement of convertible sub-ordinated notes

N/A

$60

Guilford agreed to sell $60M of convertible subordinated notes, which are convertible into stock at $6.24 per share (6/13)

Hollis-Eden Pharmaceuticals Inc. (HEPH)

Private placement of common stock

1.3S

$15

Hollis-Eden raised about $15M through the private placement (6/20)

ICOS
Corp.
(ICOS)

Private placement of convertible subordinated notes

N/A

$250

ICOS raised $250M with a private placement of 2% convertible subordinated notes due 2023 (6/17)

Inex Pharmaceuticals Corp. (Canada; TSE:IEX)

Private placement of common stock

4.6S

C$25.07 (US$18.58)

Inex raised US$18.58M in the financing with investors BMO Nesbitt Burns, Raymond James, Desjardins Securities and Orion Securities; the investors also have an overallotment option on 690,000 shares in the bought-deal financing (6/27)

Integrated BioPharma Inc. (AMEX:INB)

Private placement of convertible preferred stock

0.0095S

$9.5

Integrated raised $9.5M from the sale of 9,500 newly issued shares of Series A convertible preferred stock priced at $1,000 apiece (6/30)

Introgen Therapeutics Inc. (INGN)

Private placement of common stock

2S

$11.5

Introgen raised $11.5M through the private placement of 2M common shares (6/18)

Labopharm Inc. (Canada; TSE:DDS)

Private placement of common stock

N/A

C$22 (US$16.3)

Labopharm raised about US$16.3M in a bought-deal financing led by National Bank Financial, which also has a 15% overallotment option (6/27)

Medicure Inc.
(Canada; TSE:MPH)

Private placement of common stock

8.2S

C$7 (US$5.65)

Medicure raised US$5.65M with the sale of 8.2M common shares to Research Capital Corp., First Associates Investments Inc. and Paradigm Capital Inc. (6/13)

MedMira Inc.
(Canada; VSE:MIR)

Loan facility

0.037S and 0.147W

C$0.625 (US$0.46)

Company completed arrangements for a US$460,476 loan facility with individual Martin Fiuffre; the company agreed to issue the lender 36,765 common shares and 147,059 warrants (6/9)

Nektar Therapeutics (NKTR)

Private placement of convertible subordinated notes

N/A

$100

Nektar raised $100M in a private offering to qualified institutional buyers (6/23)

NPS Pharmaceuticals Inc. (NPSP)

Private placement of convertible notes

N/A

$170

NPS raised $170M through the private placement of convertible notes (6/13)

Oncolytics Biotech Inc. TSE:ONC)

Private placement of common stock

6.9S

C$2.6 (US$1.9)

Oncolytics raised US$1.9M through the sale of 6.9M shares of Transition Therapeutics Inc., which was (Canada; ONCY; all of its interest in the company (6/6)

Oncolytics Biotech Inc. (Canada; ONCY; TSE:ONC)

Private placement of units

2U

C$6 (US$4.4)

Oncolytics raised US$4.4M through the private sale of 2M units (6/10)

Ortec International Inc. (OTC BB: ORTN)

Private placement of convertible preferred stock

N/A

$5.34

Ortec raised $5.34M in a private placement of convertible preferred stock at a fixed price of 20 cents each (6/2)

Orthovita
Inc.
(VITA)

Private placement of common stock and warrants

4.9S and W for 0.979S

$13.7

Orthovita raised about $13.7M after selling about 4.9M shares; investors also received five-year warrants to purchase about 979,000 common shares; SG Cowen Securities Corp. acted as the offering's placement agent (6/27)

OxiGene
Inc.
(OXGN)

Private placement of common stock

1.5S

$15

OxiGene raised $15M with the sale of 1.5M shares to three institutional investors (6/10)

Peplin Biotech
Ltd.
(Australia; ASX:PEP)

Private placement of common stock

5S

A$3.5 (US$2.3)

Peplin Biotech raised US$2.3M with the placement of 5M shares to domestic and international institutional investors at 70 cents per share (6/2)

Peregrine Pharmaceuticals
Inc.
(PPHM)

Private placement of common stock and warrants

2.4S and 0.15W

$2

Peregrine raised $2M through the sale of 2.4M shares and 150,000 warrants (6/10)

Peregrine Pharmaceuticals Inc. (PPHM)

Private placement of common stock and the exercise of outstanding warrants

1.6S and W for 3S

$4

Peregrine raised $1.8M with the issuance of 1.6M shares to seven institutional investors; it also received $2.2M from the exercise of existing outstanding warrants issued in August 2002 for about 3M shares (6/27)

Pharming Group NV (the Netherlands; Pink Sheets: PHGUF)

Private placement of common stock

3.15S

€4 (US$4.69)

Pharming Group raised US$4.69M from European Bioscience Investments through the sale of 3.15M shares (6/4**)

Pharmos Corp.
(PARS)

Private placement of common stock and warrants

9.41S

$8

Pharmos raised $8M, placing 9.41M shares and five-year warrants covering another 30% of the shares with 10 institutional investors; Rodman & Renshaw acted as lead placement agent (6/3)

Protein Polymer Technologies Inc. (OTC BB:PPTI)

Private placement of preferred stock and warrants

N/A

$0.25

Protein Polymer raised $250,000 in a private placement of Series I convertible preferred stock and warrants; the company raised $3M in March in the first closing of the financing (6/10)

Proterion Corp. (AMEX:PRC)

Credit facility

N/A

$1

Proterion raised $1M in a credit facility from KBK Financial Inc. (6/26)

Questcor Pharmaceuticals Inc. (AMEX:QSC)

Private placement of common shares

4.98S and W for 3S

$5

Questcor raised $5M by issuing 4.98M shares; it also issued warrants for another 3M shares to the investors led by Broadwood Capital; other investors were Craig Drill Capital, Midsummer Capital, Islandia LP and others (6/17)

RegeneRx Biopharmaceuticals
Inc.
(OTC BB:RGRX)

Private placement of common stock

3.18S

$2

RegeneRx raised $2M in proceeds from a private placement of stock with Defiante Farmaceutica Unipessoal LDA, a subsidiary of Sigma-Tau Finanziaria SpA (6/11)

Rigel Pharmaceuticals Inc. (RIGLD)

Private placement of common stock and warrants

72S and W for 14.4S

$46

Rigel raised $46M after closing a private placement of common stock and warrants exercisable for additional shares of common stock; investors were MPM Capital, Frazier & Co., Alta Partners and HBM BioVentures AG (6/27)

SIGA Technologies
Inc.
(SIGA)

Private placement of common stock and warrants

1.25S and W for 0.625S

$1.5

SIGA raised $1.5M from a private placement of 1.25M shares and warrants for 625,000 shares (6/24)

SuperGen Inc.
(SUPG)

Private placement of senior convertible notes

N/A

$21.25

SuperGen raised $21.25M in the financing; Rodman & Renshaw Inc. acted as placement agent (6/25)

Synthetic Blood International Inc.
(OTC BB: SYBD)

Private placement of common stock

N/A

$2

Synthetic Blood raised $2M in funds from a private investment source in Europe (6/24)

Targeted Genetics Corp. (TGEN)

Private placement of common stock

7.8S

$17.55

Targeted Genetics raised $17.55M after placing 7.8M shares at $2.25 each; Roth Capital Partners LLC acted as placement agent for the financing, which included investments from Mainfield Enterprise Inc., Cranshire Capital LP, Smithfield Fiduciary LLC and Portside Growth & Opportunity Fund (6/18)

The Immune Response Corp. (IMNR)

Private placement of promissory notes

N/A

$1

The Immune Response Corp. raised $1M in the private placement with accredited investors (6/26)

Tm Bioscience Corp. (Canada; VSE:TMC)

Private placement of units

23.2U

C$5 (US$3.7)

Tm Bioscience raised US$3.7M with the issuance of 23.2M units, each consisting of one common share and a half-share purchase warrant; Loewen, Ondaatje, McCutcheon Ltd. is lead placement agent, with support from Harris Partners Ltd. (6/16)

VaxGen Inc.
(VXGN)

Private placement of common stock

1.6S

$7

VaxGen raised $7M through the sale of about 1.6M shares of comon stock to a single institutional investor; Granite Financial Group Inc. acted as placement agent and Enable Capital LLC acted as adviser (6/9)

Vion
Pharmaceuticals
Inc.
(VION)

Private placement of common stock

3.8S

$5

Vion raised $5M, issuing 3.8M shares to several institutional investors; Rodman & Renshaw acted as the transaction's placement agent, and Gerard Klauer Mattison acted as Vion's financial adviser (6/19)


Notes:

This chart does not include real estate or manufacturing plant financings.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

** Denotes the date the item ran in BioWorld International.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange.